Comparison of Chest CT Images Featured with Ground Grass Opacity between COVID-19 Pneumonia and Early-Stage Lung Cancer in Wuhan, China: A Single-Centered, Retrospective, Observational Study
Heng Meng,Rui Xiong,Ruyuan He,Weichen Lin,Bo Hao,Lin Zhang,Zilong Lu,Xiaokang Shen,Tao Fan,Wenyang Jiang,Wenbing Yang,Tao Li,Jun Chen,Geng Qing
DOI: https://doi.org/10.2139/ssrn.3551427
2020-01-01
SSRN Electronic Journal
Abstract:Background: An outbreak of the coronavirus disease 2019 (COVID-19) pneumonia caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) started in December 2019, in Wuhan, China. Ground Glass Opacity (GGO) is the most common image of CT findings in COVID-19 pneumonia. GGO is also the main CT imaging features of early-stage lung cancer. We aimed to characterize and compare the CT images featured with GGO between patients with COVID-19 pneumonia and patients with early-stage lung cancer, to facilitate early identification of COVID-19 pneumonia. Methods: Patients with COVID-19 pneumonia (confirmed by RT-PCR) with GGO-manifested CT images who were admitted to Renmin Hospital of Wuhan University between January 13, 2020 and February 13, 2020, as COVID-19 pneumonia group, and patients with early-stage lung cancer with GGO-manifested CT images admitted between January 2019 and January 2020, as early-stage lung cancer group, were retrospectively enrolled. Demographic data, symptoms, laboratory results, Epidemiological history, comorbidities and imaging features were collected, analysed and compared between the two groups. Findings: A total of 84 COVID-19 pneumonia patients (39 men and 45 women) and 92 patients with early-stage lung cancer (40 men and 52 women) were enrolled in this retrospective study. In our cohort, there was no obvious predilection for gender, age and comorbidities in two groups. In COVID-19 pneumonia group, 75 (89.3%) patients were non-severe cases, the most common symptoms at onset were fever (57, 67.9%) and cough (38, 45.2%), 15 (17.9%) patients had no symptom. And in early-stage lung cancer group, only 8 (8.7%) patients had cough. In COVID-19 pneumonia group, 71 (84.5%) patients had definite history of exposure to SARS-CoV-2. Except for significantly lower lymphocyte count and higher C-reactive protein in COVID-19 group, there are no other abnormal of laboratory results between two groups. The GGO features in COVID-19 pneumonia group were multifocal (71,84.5%), multilobal involved (66,78.6%), bilateral (50,59.5%), peripheral distribution (72,85.7%), often accompanied by subpleural bands, fine reticulation , air bronchogram, halo sign or vascular enlargement signs. The GGO manifestations in early-stage lung cancer were characterized by unilateral, single focus and involvement of one lobe. Compared with stability of early-stage lung cancer, the extent of lesions on CT images showed a marked progression corresponding with the evolution of COVID-19 pneumonia within one week. Interpretation: Compared with CT images of GGO in patients with early-stage lung cancer, GGO features in patients with COVID-19 pneumonia have their own characteristics and t he evolution of GGO images corresponds with the progression of disease in a short time. The evaluation of GGO features combined with clinical, epidemiological and laboratory findings would facilitate the early detection and identification of COVID-19 pneumonia. For the asymptomatic patients with GGO manifestation on CT findings, it is particularly essential to recheck chest CT within one week. Fully understanding the imaging features and differential diagnosis of COVID-19 will facilitate early detection and isolation of patients with SARS-CoV-2. Funding Statement: This work was supported by National Natural Science Foundation of China (81770095,81700093).Declaration of Interests: The authors declare no conflict of interests.Ethics Approval Statement: The study was a retrospective analysis and was approved by the Ethics Committee of Renmin Hospital of Wuhan University (approved number: WDRY2020-K009), which waived the requirement for patients’ informed consent referring to the CIOMS guideline.